Table 1 General, clinicopathologic, treatment, and follow-up characteristics for the 715 gallbladder cancer patients with different surgery treatments
From: Impact of surgical strategies on the survival of gallbladder cancer patients: analysis of 715 cases
Variates | Total | Simple resection | Radical resection | Palliative surgery | p |
|---|---|---|---|---|---|
(n = 715) N (%) | (n = 126) N (%) | (n = 349) N (%) | (n = 240) N (%) | ||
Sources | 0.2488 | ||||
Urban | 299 (41.8) | 56 (44.4) | 153 (43.8) | 90 (37.5) | |
Country | 416 (58.2) | 70 (55.6) | 196 (56.2) | 150 (62.5) | |
Ages (years) | 0.0198 | ||||
< 60 | 275 (38.5) | 41 (32.5) | 154 (44.1) | 80 (33.3) | |
60–69 | 264 (36.9) | 48 (38.1) | 125 (35.8) | 91 (37.9) | |
≥ 70 | 176 (24.6) | 37 (29.4) | 70 (20.1) | 69 (28.8) | |
Sex | 0.0573 | ||||
Female | 258 (36.1) | 34 (27) | 130 (37.2) | 94 (39.2) | |
Male | 457 (63.9) | 92 (73) | 219 (62.8) | 146 (60.8) | |
BMI (Kg/m2) | 0.293 | ||||
< 28 | 613 (85.7) | 109 (86.5) | 301 (86.2) | 203 (84.6) | |
≥ 28 | 80 (11.2) | 10 (7.9) | 39 (11.2) | 31 (12.9) | |
Unknown | 22 (3.1) | 7 (5.6) | 9 (2.6) | 6 (2.5) | |
Smoking history | 0.3083 | ||||
No | 568 (79.4) | 105 (83.3) | 279 (80) | 184 (76.7) | |
Yes | 147 (20.6) | 21 (16.7) | 70 (20) | 56 (23.3) | |
Gallbladder location of tumor | < 0.0001 | ||||
Fundus | 208 (29.1) | 45 (35.7) | 123 (35.2) | 40 (16.7) | |
Body | 321 (44.9) | 62 (49.2) | 151 (43.3) | 108 (45) | |
Neck | 150 (21) | 19 (15.1) | 75 (21.5) | 56 (23.3) | |
Unknown | 36 (5) | 0 | 0 | 36 (15) | |
Clinical staging | < 0.0001 | ||||
I | 35 (4.9) | 20 (15.9) | 15 (4.3) | 0 | |
II | 82 (11.5) | 37 (29.4) | 45 (12.9) | 0 | |
III | 291 (40.7) | 59 (46.8) | 214 (61.3) | 18 (7.5) | |
IV | 307 (42.9) | 10 (7.9) | 75 (21.5) | 222 (92.5) | |
T stage | < 0.0001 | ||||
T1 | 34 (4.8) | 16 (12.7) | 18 (5.2) | 0 | |
T2 | 92 (12.9) | 38 (30.2) | 53 (15.2) | 1 (0.4) | |
T3 | 381 (53.3) | 64 (50.8) | 255 (73.1) | 62 (25.8) | |
T4 | 125 (17.5) | 4 (3.2) | 22 (6.3) | 99 (41.3) | |
Unknown | 83 (11.6) | 4 (3.2) | 1 (0.3) | 78 (32.5) | |
N stage | < 0.0001 | ||||
N0 | 276 (38.6) | 70 (55.6) | 197 (56.4) | 9 (3.8) | |
N1 | 88 (12.3) | 5 (4) | 77 (22.1) | 6 (2.5) | |
N2 | 90 (12.6) | 3 (2.4) | 58 (16.6) | 29 (12.1) | |
Unknown | 211 (29.5) | 48 (38.1) | 17 (4.9) | 146 (60.8) | |
M stage | < 0.0001 | ||||
M0 | 524 (73.3) | 119 (94.4) | 338 (96.8) | 67 (27.9) | |
M1 | 158 (22.1) | 6 (4.8) | 8 (2.3) | 144 (60) | |
Unknown | 33 (4.6) | 1 (0.8) | 3 (0.9) | 29 (12.1) | |
Grade | < 0.0001 | ||||
Well-differentiated | 27 (3.8) | 13 (10.3) | 11 (3.2) | 3 (1.3) | |
Moderately differentiated | 112 (15.7) | 30 (23.8) | 73 (20.9) | 9 (3.8) | |
Poorly differentiated | 184 (25.7) | 28 (22.2) | 122 (35) | 34 (14.2) | |
Unknown | 392 (54.8) | 55 (43.7) | 143 (41) | 194 (80.8) | |
CA199 | 0.0266 | ||||
< 27 U/mL | 262 (36.6) | 59 (46.8) | 168 (53.2) | 35 (14.6) | |
≥ 27 U/mL | 388 (54.3) | 49 (38.9) | 158 (45.3) | 181 (75.4) | |
Unknown | 65 (9.1) | 18 (14.3) | 23 (6.6) | 24 (10) | |
CA242 | |||||
< 20 IU/mL | 296 (41.4) | 61 (48.4) | 171 (49) | 64 (26.7) | < 0.0001 |
≥ 20 IU/mL | 311 (43.5) | 33 (26.2) | 131 (37.5) | 147 (61.3) | |
Unknown | 108 (15.1) | 32 (25.4) | 47 (23.5) | 29 (12.1) | |
With chronic disease | 0.2935 | ||||
No | 433 (60.6) | 74 (58.7) | 204 (58.5) | 155 (64.6) | |
Yes | 282 (39.4) | 52 (41.3) | 145 (41.5) | 85 (35.4) | |
Gallstone | < 0.0001 | ||||
No | 321 (44.9) | 34 (27) | 162 (46.4) | 125 (52.1) | |
Yes | 394 (55.1) | 92 (73.1) | 187 (53.6) | 115 (47.9) | |
Adjuvant therapy | < 0.0001 | ||||
None | 537 (75.1) | 96 (76.2) | 239 (68.5) | 202 (84.2) | |
Received | 178 (24.9) | 30 (23.8) | 110 (31.5) | 38 (15.8) | |
Follow-up | |||||
Alive | 212 (29.7) | 59 (46.8) | 136 (39) | 17 (7.1) | |
3-year survival | 254 (35.5) | 69 (54.8) | 134 (38.4) | 51 (21.3) | |
Months, median(95% CI) | 27 (22–31) | 51 (41–69) | 34 (28–44) | 10 (7–14) |